We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases
Eyevensys is a private biotechnology company developing a novel approach in the treatment of major ophthalmic diseases. We create a bio therapeutics factory in the eye to allow safe local sustained production of therapeutic proteins, an approach that can address a wide range of ophthalmic diseases.
Latest News
Dec 12, 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer

Paris (France), December 12th, 2017 – Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the...

Sep 13, 2017
Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression...

Our approach is based on Eyevensys’ EyeCET platform, the first non-viral technology that allows reprogramming of the ciliary muscle cells for the production of well-known therapeutic proteins.

Eyevensys’ lead product, EYS606 is being developed as a potential new treatment for non-infectious uveitis. EYS606 has been granted an Orphan designation by the EMA for the treatment of NIU and is expected to enter into clinic imminently.

The EyeCET treatment procedure, which takes less than 5 minutes, is designed to provide the patient with a local and safe treatment with long lasting effects, between 3 and up to potentially 12 months.


Eyevensys’ vision is to harness our EyeCET platform to address major unfulfilled needs in the treatment of sight threatening ophthalmic diseases.